Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $150
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $140 to $150.